Leflunomide Sandoz

Leflunomide, the active ingredient in Leflunomide Sandoz, is an immunomodulatory agent presented as an oral tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients. GNH USA supplies Leflunomide Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease-modifying antirheumatic drug (DMARD) that targets inflammatory pathways in autoimmune arthritis.

Rheumatoid arthritis: reduces disease activity, slows joint damage, and improves functional ability. Psoriatic arthritis: alleviates joint inflammation, skin lesions, and prevents structural progression.

Leflunomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea or abdominal discomfort - Nausea and loss of appetite - Elevated liver enzymes - Hypertension - Alopecia or thinning hair - Rash or mild skin irritation

Serious or Rare Side Effects: - Severe liver injury or hepatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Bone marrow suppression leading to anemia or leukopenia - Interstitial lung disease or pulmonary fibrosis

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on risk mitigation.

Monitor liver function: obtain baseline and periodic liver enzyme tests. Monitor blood pressure: watch for hypertension and treat as needed. Avoid in pregnancy: teratogenic risk requires effective contraception for women of child‑bearing potential. Assess infection risk: screen for active infections and avoid use in severe infections. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Leflunomide can alter the pharmacokinetics or pharmacodynamics of several co‑administered medicines.

Major Interactions (Avoid): - Methotrexate: increased toxicity, especially hepatic and hematologic. - Warfarin: enhanced anticoagulant effect, risk of bleeding. - Cholesterol‑binding resins (e.g., cholestyramine): reduced leflunomide absorption.

Moderate Interactions (Monitor Closely): - Statins: heightened risk of myopathy or rhabdomyolysis. - Antihypertensives: additive blood‑pressure lowering effect. - Live vaccines: diminished immunogenic response, consider postponement.